ProShares UltraPro Nasdaq Biotechnology
Not enough financial coverage to compute a composite score for UBIO. This is typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available data still render below.
Company
The investment seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the NASDAQ Biotechnology Index (the index). The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical.
- IPO
- 2015
Price Chart
Performance & Tape
- 52W High
- $34.80
- 52W Low
- $13.13
- 50D MA
- $17.77
- 200D MA
- $17.77
- Beta
- 3.15
- Avg Volume
- 0
Get TickerSpark's AI analysis on UBIO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our UBIO Coverage
We haven't published any research on UBIO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate UBIO Report →